PL2532366T3 - Kompozycja farmaceutyczna do leczenia i/lub zapobiegania nowotworowi - Google Patents

Kompozycja farmaceutyczna do leczenia i/lub zapobiegania nowotworowi

Info

Publication number
PL2532366T3
PL2532366T3 PL11739881T PL11739881T PL2532366T3 PL 2532366 T3 PL2532366 T3 PL 2532366T3 PL 11739881 T PL11739881 T PL 11739881T PL 11739881 T PL11739881 T PL 11739881T PL 2532366 T3 PL2532366 T3 PL 2532366T3
Authority
PL
Poland
Prior art keywords
treating
pharmaceutical composition
preventing cancer
cancer
preventing
Prior art date
Application number
PL11739881T
Other languages
English (en)
Inventor
Shinichi Kobayashi
Fumiyoshi Okano
Takanori Saito
Original Assignee
Toray Industries, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toray Industries, Inc. filed Critical Toray Industries, Inc.
Publication of PL2532366T3 publication Critical patent/PL2532366T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732Antibody-dependent cellular cytotoxicity [ADCC]
PL11739881T 2010-02-04 2011-02-04 Kompozycja farmaceutyczna do leczenia i/lub zapobiegania nowotworowi PL2532366T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2010023453 2010-02-04
JP2010183161 2010-08-18

Publications (1)

Publication Number Publication Date
PL2532366T3 true PL2532366T3 (pl) 2017-02-28

Family

ID=44355527

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11739881T PL2532366T3 (pl) 2010-02-04 2011-02-04 Kompozycja farmaceutyczna do leczenia i/lub zapobiegania nowotworowi

Country Status (16)

Country Link
US (1) US8937160B2 (pl)
EP (1) EP2532366B1 (pl)
JP (1) JP5742713B2 (pl)
KR (1) KR101801667B1 (pl)
CN (1) CN102821789B (pl)
AU (1) AU2011211698B2 (pl)
BR (1) BR112012018951C8 (pl)
CA (1) CA2788716C (pl)
DK (1) DK2532366T3 (pl)
ES (1) ES2606173T3 (pl)
HU (1) HUE030742T2 (pl)
MX (1) MX342291B (pl)
PL (1) PL2532366T3 (pl)
PT (1) PT2532366T (pl)
RU (1) RU2597971C2 (pl)
WO (1) WO2011096533A1 (pl)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2733223C (en) 2008-08-05 2018-02-27 Toray Industries, Inc. Pharmaceutical composition comprising anti-caprin-1 antibody for treatment and prevention of cancers
MX2011001445A (es) * 2008-08-05 2011-04-05 Toray Industries Metodo para detectar cancer.
MX340015B (es) 2010-02-04 2016-06-22 Toray Industries Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
RU2624029C2 (ru) 2010-02-04 2017-06-30 Торэй Индастриз, Инк. Лекарственный препарат для лечения и/или профилактики рака
PT2532365T (pt) 2010-02-04 2016-07-28 Toray Industries Composição farmacêutica para o tratamento e/ou a prevenção do cancro
HUE030742T2 (en) 2010-02-04 2017-06-28 Toray Industries A pharmaceutical composition for the treatment and / or prevention of cancer
KR101871704B1 (ko) 2010-02-04 2018-06-27 도레이 카부시키가이샤 암의 치료 및/또는 예방용 의약 조성물
US8709418B2 (en) 2010-02-04 2014-04-29 Toray Industries, Inc. Pharmaceutical composition for treating CAPRIN-1 expressing cancer
PT2740796T (pt) 2011-08-04 2017-07-26 Toray Industries Composição farmacêutica para o tratamento e/ou profilaxia de cancro
KR101980554B1 (ko) 2011-08-04 2019-05-21 도레이 카부시키가이샤 암의 치료 및/또는 예방용 의약 조성물
WO2013018885A1 (ja) 2011-08-04 2013-02-07 東レ株式会社 膵臓癌の検出方法
BR112014002614B1 (pt) 2011-08-04 2022-09-20 Toray Industries, Inc Anticorpo ou um fragmento do mesmo, composição farmacêutica, combinação farmacêutica, uso de um anticorpo, uso de uma composição farmacêutica e uso de uma combinação farmacêutica
EP2740793B1 (en) 2011-08-04 2017-11-29 Toray Industries, Inc. Drug composition for cancer treatment and/or prevention
EP2740489B1 (en) 2011-08-04 2016-10-05 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of pancreatic cancer
ES2672695T3 (es) 2011-08-04 2018-06-15 Toray Industries, Inc. Composición farmacéutica para el tratamiento y/o la profilaxis del cáncer
MX363136B (es) * 2012-02-21 2019-03-12 Toray Industries Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX360211B (es) * 2012-02-21 2018-10-24 Toray Industries Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
WO2013125636A1 (ja) 2012-02-21 2013-08-29 東レ株式会社 癌の治療及び/又は予防用医薬組成物
IN2014KN01715A (pl) 2012-02-21 2015-10-23 Toray Industries
PL2832366T3 (pl) 2012-03-30 2018-04-30 Toray Industries, Inc. Kompozycja farmaceutyczna do leczenia i/lub zapobiegania rakowi pęcherzyka żółciowego
CA2869120C (en) 2012-03-30 2023-05-23 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of liver cancer
JP6244912B2 (ja) 2012-07-19 2017-12-13 東レ株式会社 癌の検出方法
RU2646466C2 (ru) 2012-07-19 2018-03-05 Торэй Индастриз, Инк. Метод детекции рака
AU2014274660B2 (en) 2013-06-06 2019-05-16 Pierre Fabre Médicament Anti-C10orf54 antibodies and uses thereof
CA2918989C (en) 2013-08-09 2021-11-02 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
KR20230149857A (ko) 2016-07-07 2023-10-27 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 항체-애쥬번트 접합체
AU2017348734A1 (en) 2016-10-28 2019-05-16 Toray Industries, Inc. Pharmaceutical composition for cancer treatment and/or prevention
BR112020019935A2 (pt) 2018-03-30 2021-01-26 Toray Industries, Inc. medicamento para o tratamento e/ou prevenção do câncer, agentes que aumentam a eficácia de um fármaco e método de tratamento e/ou prevenção do câncer
AU2020241686A1 (en) 2019-03-15 2021-11-04 Bolt Biotherapeutics, Inc. Immunoconjugates targeting HER2
JPWO2021182570A1 (pl) 2020-03-12 2021-09-16
JPWO2021182572A1 (pl) 2020-03-12 2021-09-16
WO2021182573A1 (ja) 2020-03-12 2021-09-16 東レ株式会社 癌の治療及び/又は予防のための医薬品
EP4119160A4 (en) 2020-03-12 2024-04-03 Toray Industries MEDICINE FOR THE TREATMENT AND/OR PREVENTION OF CANCER
US20230165957A1 (en) 2020-03-12 2023-06-01 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
JPWO2022270523A1 (pl) 2021-06-23 2022-12-29
AU2022298240A1 (en) 2021-06-23 2024-01-18 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
KR20240042416A (ko) 2021-07-27 2024-04-02 도레이 카부시키가이샤 암의 치료 및/또는 예방을 위한 의약품
KR20240041917A (ko) 2021-07-27 2024-04-01 도레이 카부시키가이샤 암의 치료 및/또는 예방을 위한 의약품
JPWO2023008461A1 (pl) 2021-07-27 2023-02-02
AU2022338463A1 (en) 2021-09-03 2024-03-21 Toray Industries, Inc. Pharmaceutical composition for cancer treatment and/or prevention

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
CA2194907A1 (en) 1994-07-13 1996-02-01 Kouji Matsushima Reshaped human antibody against human interleukin-8
US5698396A (en) 1995-06-07 1997-12-16 Ludwig Institute For Cancer Research Method for identifying auto-immunoreactive substances from a subject
WO2001032910A2 (en) 1999-10-29 2001-05-10 Human Genome Sciences, Inc. 27 human secreted proteins
FR2761994B1 (fr) 1997-04-11 1999-06-18 Centre Nat Rech Scient Preparation de recepteurs membranaires a partir de baculovirus extracellulaires
AU752730B2 (en) 1998-04-03 2002-09-26 Chugai Seiyaku Kabushiki Kaisha Humanized antibody against human tissue factor (TF) and process for constructing humanized antibody
US20030118599A1 (en) 1999-04-02 2003-06-26 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
RU2234942C2 (ru) 1998-07-14 2004-08-27 Корикса Корпорейшн Выделенный опухолевый полипептид предстательной железы и кодирующий его полинуклеотид
TW200532020A (en) 1998-07-14 2005-10-01 Corixa Corp Compositions and methods for therapy and diagnosis of prostate cancer
US6969518B2 (en) 1998-12-28 2005-11-29 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6335170B1 (en) 1999-02-22 2002-01-01 Torben F. Orntoft Gene expression in bladder tumors
AU4185100A (en) * 1999-04-02 2000-10-23 Corixa Corporation Compounds for therapy and diagnosis of lung cancer and methods for their use
US6444425B1 (en) 1999-04-02 2002-09-03 Corixa Corporation Compounds for therapy and diagnosis of lung cancer and methods for their use
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
US20020006404A1 (en) 1999-11-08 2002-01-17 Idec Pharmaceuticals Corporation Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
CA2404233A1 (en) 2000-03-29 2001-10-04 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
ES2295228T3 (es) 2000-11-30 2008-04-16 Medarex, Inc. Roedores transcromosomicos transgenicos para la preparacion de anticuerpos humanos.
US7919467B2 (en) * 2000-12-04 2011-04-05 Immunotope, Inc. Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
US20040029114A1 (en) 2001-01-24 2004-02-12 Eos Technology, Inc. Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer
RU2306952C2 (ru) 2001-01-31 2007-09-27 Байоджен Айдек Инк. Лечение в-клеточных злокачественных опухолей с использованием комбинации применений, связанных с антителами, уменьшающими количество b-клеток, и с иммуномодулирующими антителами
AU2002311787A1 (en) * 2001-03-28 2002-10-15 Zycos Inc. Translational profiling
WO2002083070A2 (en) * 2001-04-10 2002-10-24 Corixa Corporation Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
WO2002092001A2 (en) 2001-05-11 2002-11-21 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
KR100583331B1 (ko) 2001-05-11 2006-05-26 기린 비루 가부시키가이샤 인간 항체 λ 경쇄 유전자를 포함하는 인간 인공 염색체 및 자손 전달 가능한 상기 인간 인공 염색체를 포함하는 비인간 동물
US20030190640A1 (en) 2001-05-31 2003-10-09 Mary Faris Genes expressed in prostate cancer
RU2319709C2 (ru) * 2001-07-17 2008-03-20 Рисерч Дивелопмент Фаундейшн Терапевтические агенты, содержащие проапоптозные белки
US20040142325A1 (en) 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
JP2005535290A (ja) * 2002-02-22 2005-11-24 ジェネンテック・インコーポレーテッド 免疫関連疾患の治療のための組成物と方法
US20050003390A1 (en) * 2002-05-17 2005-01-06 Axenovich Sergey A. Targets for controlling cellular growth and for diagnostic methods
US20040126379A1 (en) 2002-08-21 2004-07-01 Boehringer Ingelheim International Gmbh Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and chemotherapeutic agents
US20060121029A1 (en) 2002-08-30 2006-06-08 Hiroshi Shiku Method and composition for regulating the activity of regulatory t cells
WO2004047728A2 (en) * 2002-11-26 2004-06-10 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
WO2004076682A2 (en) 2003-02-26 2004-09-10 Surromed, Inc. Targets for controlling cellular growth and for diagnostic methods
AU2004235382A1 (en) 2003-04-29 2004-11-11 Wyeth Methods for diagnosing AML and MDS differential gene expression
US20060019256A1 (en) 2003-06-09 2006-01-26 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US20070048738A1 (en) 2003-07-14 2007-03-01 Mayo Foundation For Medical Education And Research Methods and compositions for diagnosis, staging and prognosis of prostate cancer
US20050032113A1 (en) 2003-07-17 2005-02-10 Mitsubishi Pharma Corporation Membrane protein library for proteome analysis and method for preparing same
MXPA06010715A (es) 2004-03-19 2007-05-23 Imclone Systems Inc Anticuerpo del receptor del factor de crecimiento humano anti-epidermico.
PE20060287A1 (es) 2004-03-30 2006-05-16 Glaxo Group Ltd INMUNOGLOBULINAS DE UNION SELECTIVA A hOSM
WO2005100998A2 (en) 2004-04-16 2005-10-27 Europroteome Ag Membrane markers for use in cancer diagnosis and therapy
DE102004026135A1 (de) 2004-05-25 2006-01-05 Immatics Biotechnologies Gmbh An MHC-Moleküle bindende Tumor-assoziierte Peptide
WO2006002378A2 (en) 2004-06-23 2006-01-05 Avalon Pharmaceuticals Determining cancer-linked genes and therapeutic targets using molecular cytogenetic methods
CN101141981A (zh) 2005-01-21 2008-03-12 健泰科生物技术公司 Her抗体的固定剂量给药
US7858324B2 (en) 2005-02-18 2010-12-28 Children's Medical Center Corporation Cyr61 as a biomarker for diagnosis and prognosis of cancers of epithelial origin
NZ560976A (en) 2005-03-11 2011-06-30 Univ Johns Hopkins Biomarkers for ovarian cancer and endometrial cancer: hepcidin
JP2006316040A (ja) 2005-05-13 2006-11-24 Genentech Inc Herceptin(登録商標)補助療法
US8014957B2 (en) 2005-12-15 2011-09-06 Fred Hutchinson Cancer Research Center Genes associated with progression and response in chronic myeloid leukemia and uses thereof
EP1991701A4 (en) * 2006-02-14 2010-03-17 Dana Farber Cancer Inst Inc COMPOSITIONS, KITS, AND METHODS FOR IDENTIFYING, EVALUATING, PREVENTING, AND TREATING CANCER
US20100015724A1 (en) 2006-08-17 2010-01-21 Peter Hornbeck Lysine acetylation sites
US20080107668A1 (en) 2006-08-30 2008-05-08 Immunotope, Inc. Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
US7615349B2 (en) 2006-09-07 2009-11-10 H. Lee Moffitt Cancer Center And Research Institute, Inc. Melanoma gene signature
WO2008059252A2 (en) 2006-11-15 2008-05-22 Oxford Biomedica (Uk) Limited Methods and composition fro t cell receptors which recognize 5t4 antigen
JP2010023453A (ja) 2008-07-24 2010-02-04 Seiko Epson Corp 流体噴射装置のメンテナンス方法及び流体噴射装置
CA2733223C (en) * 2008-08-05 2018-02-27 Toray Industries, Inc. Pharmaceutical composition comprising anti-caprin-1 antibody for treatment and prevention of cancers
PL2324842T3 (pl) 2008-08-05 2015-08-31 Toray Industries Środek indukujący odporność
MX2011001445A (es) 2008-08-05 2011-04-05 Toray Industries Metodo para detectar cancer.
JP2010183161A (ja) 2009-02-03 2010-08-19 Toshiba Corp カメラシステム
PT2532365T (pt) * 2010-02-04 2016-07-28 Toray Industries Composição farmacêutica para o tratamento e/ou a prevenção do cancro
RU2624029C2 (ru) 2010-02-04 2017-06-30 Торэй Индастриз, Инк. Лекарственный препарат для лечения и/или профилактики рака
HUE030742T2 (en) 2010-02-04 2017-06-28 Toray Industries A pharmaceutical composition for the treatment and / or prevention of cancer
MX340015B (es) 2010-02-04 2016-06-22 Toray Industries Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
US8709418B2 (en) 2010-02-04 2014-04-29 Toray Industries, Inc. Pharmaceutical composition for treating CAPRIN-1 expressing cancer
KR101871704B1 (ko) 2010-02-04 2018-06-27 도레이 카부시키가이샤 암의 치료 및/또는 예방용 의약 조성물
EP2740489B1 (en) 2011-08-04 2016-10-05 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of pancreatic cancer
PT2740796T (pt) 2011-08-04 2017-07-26 Toray Industries Composição farmacêutica para o tratamento e/ou profilaxia de cancro
WO2013018885A1 (ja) 2011-08-04 2013-02-07 東レ株式会社 膵臓癌の検出方法

Also Published As

Publication number Publication date
MX342291B (es) 2016-09-23
RU2597971C2 (ru) 2016-09-20
JPWO2011096533A1 (ja) 2013-06-13
HUE030742T2 (en) 2017-06-28
WO2011096533A1 (ja) 2011-08-11
BR112012018951B1 (pt) 2020-05-12
US8937160B2 (en) 2015-01-20
EP2532366B1 (en) 2016-09-07
KR101801667B1 (ko) 2017-11-27
US20130045210A1 (en) 2013-02-21
BR112012018951A8 (pt) 2020-03-31
MX2012009000A (es) 2012-08-31
EP2532366A4 (en) 2013-12-04
CA2788716C (en) 2019-06-18
EP2532366A1 (en) 2012-12-12
BR112012018951C8 (pt) 2020-06-23
KR20130033347A (ko) 2013-04-03
JP5742713B2 (ja) 2015-07-01
CN102821789B (zh) 2016-03-02
AU2011211698A1 (en) 2012-08-23
BR112012018951B8 (pt) 2020-06-09
DK2532366T3 (da) 2017-01-02
PT2532366T (pt) 2016-12-20
BR112012018951A2 (pt) 2017-06-27
AU2011211698B2 (en) 2015-07-16
RU2012137504A (ru) 2014-03-10
ES2606173T3 (es) 2017-03-23
CN102821789A (zh) 2012-12-12
CA2788716A1 (en) 2011-08-11

Similar Documents

Publication Publication Date Title
PL2532366T3 (pl) Kompozycja farmaceutyczna do leczenia i/lub zapobiegania nowotworowi
EP2532364A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF CANCER
EP2532680A4 (en) MEDICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF CANCER
PL2740793T3 (pl) Kompozycja leku do leczenia i/lub zapobiegania nowotworowi
PL2818483T3 (pl) Kompozycja lecznicza do leczenia i/lub zapobiegania nowotworowi
EP2740795A4 (en) MEDICAMENT COMPOSITION FOR TREATMENT AND / OR PREVENTION OF CANCER
EP2740798A4 (en) DRUG COMPOSITION FOR CANCER TREATMENT AND / OR PREBUILDING
PL2532365T3 (pl) Kompozycja farmaceutyczna do leczenia i/lub zapobiegania nowotworowi
PL2532743T3 (pl) Kompozycja farmaceutyczna do leczenia i/lub zapobiegania raka
PT3351630T (pt) Composição farmacêutica compreendendo anticorpos anti caprin-1 para tratar e/ou prevenir o cancro
IL225471B (en) Preparations for the prevention and treatment of cancer
EP2818482A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND / OR PREVENTION OF CANCER
HUE046788T2 (hu) Gyógyászati készítmény rák kezelésére és/vagy megelõzésére
EP2824114A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND / OR PREVENTION OF CANCER
HUE036424T2 (hu) Gyógyászati készítmény májrák kezelésére és/vagy megelõzésére
IL251083A0 (en) Compounds and preparations for the treatment of cancer
SG10201500124VA (en) Methods and Compositions for Treating Cancer
EP2558085A4 (en) COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF CANCER
IL226095A0 (en) The history of pyridine and its use in pharmaceutical preparations for the treatment of cancer
EP2709614A4 (en) PHARMACEUTICAL COMPOSITION AND METHOD FOR THE TREATMENT OF CANCER
SG11201400976WA (en) Methods and pharmaceutical compositions for treating cancer
EP2582384A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF CANCER
EP2537031A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER
EP2902027A4 (en) ACTIVE COMPOSITION FOR THE TREATMENT OF TUMORS AND THE USE THEREOF
AU2011211693B2 (en) Pharmaceutical composition for treating and/or preventing cancer